Study Type
Interventional - Drug
completed
SIRS was a multicentre, international, randomized, controlled, double-blind placebo-controlled trial of high-risk adult patients undergoing cardiopulmonary bypass.
Patients were randomly allocated to receive 500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation, or matching placebo.
Primary endpoint:
Adjudicated.
1) Total mortality within 30 days post-surgery and;
2) Composite of total mortality, MI, stroke, renal failure, or respiratory failure within 30 days post-surgery.
Study Design
Randomized, double-blind treatment, placebo control, parallel group
NO. of Countries
18
NO. of Sites
86
NO. of Participants
7507
Study Period
2007-2014
Sponsor
PHRI
Richard Whitlock
Scientist
Richard Whitlock
Scientist
Richard Whitlock is Associate Chair, Research, and a Professor at the Department of Surgery, McMaster University. He was awarded the inaugural Canada Research Chair in Cardiovascular Surgery in 2020.
As well as being a PHRI Scientist, Richard is a cardiac surgeon and intensive care physician at Hamilton Health Sciences. His clinical focus is on aortic valve intervention and aortic surgery. He is a lead investigator for the CIHR funded studies SIRS, LAAOS III, and TRICS III, which have established a network of more than 120 centres to address important questions in his field.
He has published more than 90 articles in referred journals. Medically qualified at the University of Toronto, Richard received his specialist training in cardiac surgery and critical care medicine at McMaster University. In 2012, he received his PhD in clinical epidemiology.
Amit Garg
Associate Scientist
Amit Garg
Associate Scientist
Amit Garg is the Associate Dean, Clinical Research, at the Schulich School of Medicine & Dentistry, Western University, has practiced as a staff nephrologist at the London Health Sciences Centre in London, Ontario, Canada since 2003, and is a Professor of Medicine, Epidemiology and Biostatistics at Western University, with a cross-appointment in the Department of Health Research Methods, Evidence, and Impact (HEI) at McMaster University. A past president of the Canadian Society of Nephrology, Amit Garg serves as the current Ontario Lead of the Kidney, Dialysis and Transplantation Program at ICES.
He values his ongoing collaborations with PJ Devereaux and other leading clinician-scientists at PHRI, which has led to several sub-studies funded by the Canadian Institutes of Health Research which examined the effects of perioperative interventions on the risk of acute kidney injury (off-pump cardiopulmonary bypass surgery) in the CORONARY study, and more. A current interest is in pragmatic randomized trials embedded into routine healthcare delivery.
Jessica Vincent
Program Director
Jessica Vincent
Program Director
Jessica Vincent has more than 15 years’ experience in coordinating and managing large, international clinical trials. As Associate Program Manager, she oversees interventional trials, registries, and observational research studies in the areas of perioperative medicine, cardiac surgery, and digital health.
She holds an Honours Bachelor of Science Degree from Queens University, and a Master of Clinical Epidemiology Degree from the University of Newcastle.
